What can HalioDx do for you?

O’Connor JM, Esteso F & Chacón M

Official French SARS-CoV-2 guidelines for cancer patients, a triage solution with precision medicine

Future Medicine

Testimonial: Dr Juan Manuel O’Connor (Instituto Alexander Fleming in Buenos Aires, Argentina) on the use of Immunoscore in routine practice in managing early Colon Cancer

Factsheet Immunoscore® & COVID-19 Colon Cancer Guidelines

Poster presented at ASCO20 Virtual Scientific meeting#ASCO20

Immunoscore is the most powerful parameter predicting time to recurrence and disease-free survival in T4N0 stage II colon cancer patients Abstract 4105

Marliot F, Chen X, Kirilovsky A et al.

Analytical validation of the Immunoscore and its associated prognostic value in patients with colon cancer

BMJ

Expert Opinion: The Role of Microbiota and its Impact on the Tumor Microenvironment in Colorectal Cancer | Dr Benjamin A. Weinberg, MD, Oncologist in Georgetown, Washington DC

Expert Opinion: Immunity and cancer | Dr Angela Alistar, MD, Oncologist in Morristown, NJ

Pages F, Andre T, Taieb J et al.

Prognostic and Predictive Value of the Immunoscore in Stage III Colon Cancer Patients Treated With Oxaliplatin in the Prospective IDEA France PRODIGE-GERCOR Cohort Study

Annals of Oncology

Sinicrope F, Shi Q, Hermitte F et al.

Contribution of Immunoscore and Molecular Features to Survival Prediction in Stage III Colon Cancer

JNCI Cancer Spectrum

Blair H

Immunoscore®: A Diagnostic Assay for Clinical Management of Colon Cancer

Molecular Diagnosis & Therapy volume

Franck Pagès, MD, PhD, on Selecting Patients With Advanced Colon Cancer for Treatment

Poster presented at Gastro Intestinal Symposium #GI20

Prognostic and predictive value of the Immunoscore in stage III colon cancer patients treated with mFOLFOX6 (3 vs 6 months) in the prospective IDEA France cohort study

Brochure Immunoscore® in Localized Colon Cancer

For Patients & Caregivers (English)

Brochure Immunoscore® in Localized Colon Cancer

For Healthcare Professionals (CLIA US version)

Brochure Immunoscore® in Localized Colon Cancer

For Healthcare Professionals (CE/IVD version)

Brochure Immunoscore® in Localized Colon Cancer

For Patients & Caregivers (Spanish)

Webinar Immunoscore®: IDEA France study results in Stage III Colon Cancer - Sept. 19, 2019 | Franck Pagès, Eric Van Cutsem

Angell HK, Bruni D, Barrett JC et al.

The Immunoscore: Colon Cancer and Beyond.

Clin Cancer Res.

Poster presented at ESMO GI 2019

Significant differences in outcome between Immunoscore categories in stage I colon cancer patients

Extract of an interview by Cancer.fr of Professor Thierry André, on Immunoscore® in the IDEA France study (in French)

Jérôme Galon, winner for the European Inventor Award 2019 for Immunoscore®

Poster presented at ASCO 2019

Validation of the Immunoscore Prognostic Value in Stage III Colon Cancer Patients treated with Oxaliplatin in the prospective IDEA France cohort study (PRODIGE-GERCOR).

Pages F, Andre T, Taieb J et al.

Validation of the Immunoscore prognostic value in stage III colon cancer patients treated with oxaliplatin in the prospective IDEA France cohort study (PRODIGE-GERCOR)

Journal of Clinical Oncology

Dr. Fakih Discusses the Utility of Immunoscore® in CRC

Immunoscore® Webinar New data in Stage II Colon Cancer - March 21, 2019 | Jêrome Galon, PhD

Zeitoun G, Sissy CE, Kirilovsky A et al.

The Immunoscore in the Clinical Practice of Patients with Colon and Rectal Cancers.

Chirurgia (Bucur).

Discover how Immunoscore® is predicting the risk of relapse in localized colon cancer in a short video

Poster presented at Gastrointestinal Cancers Symposium 2019

Immunoscore clinical utility to identify good prognostic Colon Cancer Stage II patients with high-risk clinico-pathological features for whom adjuvant treatment may be avoided

Poster presented at ESMO ASIA 2018

UCGI 34 - PROSCORE: A prospective study assessing whether Immunoscore® test impacts the choice of adjuvant chemotherapy, in a multidisciplinary meeting, for treating non-metastatic colon cancer patients after curative-intent surgery

Poster presented at ESMO IO 2018

MSI status plus Immunoscore to select metastatic colorectal cancer patients for immunotherapies

Poster presented at ESMO ASIA 2018

Immunoscore feasibility study in routine postsurgical pathologic review for early‐stage colon cancer (CC) cases risk‐assessment

Angelova M, Mlecnik B, Vasaturo A et al.

Evolution of Metastases in Space and Time under Immune Selection.

Cell

Webinar on “Clinical utility of Immunoscore® in colon cancer” with Marc Van Den Eynde, MD, PhD | October 17, 2017

Dr Jerome Galon on the Prognostic Value of Immunoscore, Onclive - ASCO 2016

Immunoscore® Colon Symposium - June 1, 2018, Chicago | Discussion on clinical cases

Immunoscore® Colon Symposium - June 1, 2018, Chicago | Jérôme Galon, PhD

Immunoscore® Colon Symposium - June 1, 2018, Chicago | Stanley Hamilton, MD

Pagès F, Mlecnik B, Marliot F et al.

International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study.

Lancet

Poster presented at AACR 2018

Multi-centric PD-L1 and CD8 IHC assessment in NSCLC using IMMUNOSCORE® IC previously Halioseek®) CE-IVD assay

Poster presented at ASCO GI 2018

Immunoscore provides prognostic information in low (T3N1) and high (T4 or N2) risk subsets of stage III colon carcinoma patients treated with adjuvant FOLFOX in a phase III trial [NCCTG N0147 (Alliance)

Sinicrope F, Shi Q, Hermitte F et al.

Immunoscore to provide prognostic information in low- (T1-3N1) and high-risk (T4 or N2) subsets of stage III colon carcinoma patients treated with adjuvant FOLFOX in a phase III trial (NCCTG N0147; Alliance).

J Clin Oncol.

Mlecnik B, Van den Eynde M, Bindea G et al.

Comprehensive Intrametastatic Immune Quantification and Major Impact of Immunoscore on Survival.

J Natl Cancer Inst.

Poster presented at SITC 2017

Immunoscore IC (previously Halioseek® PD‐L1/CD8), a dual CD8 and PD‐L1 IVD assay to improve NSCLC patients stratification

Poster presented at ASCO 2017

Prognostic utility of immune markers and validation of Immunoscore® in stage III colon carcinoma patients treated with adjuvant FOLFOX in a phase III trial [NCCTG N0147 (Alliance)]

Sinicrope F, Shi Q, Hermitte F et al.

Association of immune markers and Immunoscore with survival of stage III colon carcinoma (CC) patients (pts) treated with adjuvant FOLFOX: NCCTG N0147 (Alliance).

J Clin Oncol.

Galon J, Mlecnik B, Marliot F et al.

Validation of the Immunoscore (IM) as a prognostic marker in stage I/II/III colon cancer: Results of a worldwide consortium-based analysis of 1,336 patients.

J Clin Oncol.

Poster presented at AACR 2017

A new standardized CD8 and PD-L1 dual assay

Poster presented at SITC 2016

Immunoscore® analytical performance

Hermitte F

Biomarkers immune monitoring technology primer: Immunoscore® Colon.

Journal for ImmunoTherapy of Cancer

Kirilovsky A, Marliot F, El Sissy C et al.

Rational bases for the use of the Immunoscore in routine clinical settings as a prognostic and predictive biomarker in cancer patients.

Int Immunol.

Mlecnik B, Bindea G, Angell HK et al.

Integrative Analyses of Colorectal Cancer Show Immunoscore Is a Stronger Predictor of Patient Survival Than Microsatellite Instability.

Immunity

Mlecnik B, Bindea G, Kirilovsky A et al.

The tumor microenvironment and Immunoscore are critical determinants of dissemination to distant metastasis.

Sci Transl Med.

Mlecnik B, Tosolini M, Kirilovsky A et al.

Histopathologic-based prognostic factors of colorectal cancers are associated with the state of the local immune reaction.

J Clin Oncol.

Galon J, Costes A, Sanchez-Cabo F et al.

Type, density, and location of immune cells within human colorectal tumors predict clinical outcome.

Science